Business
Ligand to Report Fourth Quarter Financial Results on February 22
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 financial results after the close of the U.S.
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) will report fourth quarter 2022 financial results after the close of the U.S. financial markets on Wednesday, February 22, 2023 and will hold a conference call that same day beginning at 4:30 p.m. Eastern time. Speakers on the call will include Ligand’s CEO Todd Davis, President and COO Matt Korenberg and CFO Tavo Espinoza.\n\nConference Call and Webcast Information\n\n\n\nWhat:\n\n\n\nLigand conference call to discuss financial results and provide general business updates\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nDate:\n\n\n\nWednesday, February 22, 2023\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nTime:\n\n\n\n4:30 p.m. Eastern time (1:30 p.m. Pacific time)\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nConference Call:\n\n\n\nDial (888) 350-3452\n\n\n\n\n\n \n\n\n\nConference ID is 6501694\n\n\n\n\n\n \n\n\n\n \n\n\n\n\n\nWebcast:\n\n\n\nLive and replay webcast of the call are available here.\n\n\n\n\nAbout Ligand Pharmaceuticals\n\nLigand is a biopharmaceutical company focused on funding, enabling and supporting clinical development that allows pharmaceutical companies to create high impact medicines. Ligand does this by licensing our platform technologies, providing project financing or both. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable and diversified manner without the clinical binary risk. Our business model is based on funding mid to late-stage drug development in return for economic rights and licensing our technology platforms to help partners discover and develop medicines. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Our Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. For our Captisol partners, our team supplies our Captisol material needed for their programs. Our Pelican Expression Technology is a robust, validated, cost-effective and scalable platform for recombi...